29 completed, 14 active not recruiting, 9 recruiting, 7 terminated. 38 Phase 2, 19 Phase 1, 14 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow T-DM1: new trials by email Literature Review of T-DM1 trials Research Report on T-DM1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer Trastuzumab emtansine - HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer | Phase 2 | Terminated | Jules Bordet Institute | 87 | 2026-06-30 | 2026-08-20 |
| A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy BL-M07D1, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 1450 | 2025-06-03 | 2026-01-22 |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer GQ1005, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Recruiting | GeneQuantum Healthcare (Suzhou) Co., Ltd. | 228 | 2025-01-10 | 2026-06-29 |
| The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Nab-Paclitaxel, Paclitaxel, Docetaxel - Breast Cancer Female, Breast Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 72 | 2024-08-08 | 2026-08-06 |
| A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer BL-M07D1, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 274 | 2024-05-08 | 2026-07-23 |
| A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer DB-1303/BNT323, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Active not recruiting | DualityBio Inc. | 228 | 2024-01-29 | 2025-10-20 |
| A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer Trastuzumab emtansine - Breast Cancer | Completed | Hoffmann-La Roche | 178 | 2023-09-13 | 2025-10-10 | |
| De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer Paclitaxel, trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Active not recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 186 | 2023-09-01 | 2026-02-27 |
| A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy A166, T-DM1 - HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 365 | 2023-07-18 | 2026-05-08 |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) Trastuzumab emtansine, Tucatinib - Metastatic Solid Tumor, Brain Metastases | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-05-16 | 2026-07-16 |
| ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine - HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer | Phase 1 | Active not recruiting | Enliven Therapeutics | 198 | 2023-03-20 | 2025-07-15 |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Recruiting | NRG Oncology | 146 | 2023-03-03 | 2026-08-17 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer T-DM1, Capecitabine, External Beam Radiation Therapy 0 - Breast Cancer, Breast Cancer Stage I | Phase 2 / Phase 3 | Recruiting | University of Virginia | 45 | 2022-07-11 | 2025-04-18 |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 346 | 2022-07-05 | 2026-02-10 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 148 | 2021-10-20 | 2026-04-01 |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH trastuzumab-emtansine, Trastuzumab SC, Paclitaxel - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 500 | 2021-06-16 | 2026-08-19 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Brachyury-TRICOM, Entinostat, M7824 - Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2021-05-04 | 2022-01-11 |
| Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer | Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 120 | 2021-01-01 | 2022-06-23 |
Showing 20 of 65. Sign in to see all of them.
Breast Neoplasms (45) · Brain Neoplasms (3) · Hematologic Neoplasms (3) · Multiple Myeloma (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Lymphoma (2) · Ovarian Neoplasms (2) · Anemia (1) · Blast Crisis (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1)
Dana-Farber Cancer Institute (8) · Hoffmann-La Roche (8) · National Cancer Institute (NCI) (4) · Genentech, Inc. (3) · Jules Bordet Institute (3) · Academic and Community Cancer Research United (2) · Daiichi Sankyo (2) · OHSU Knight Cancer Institute (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Alliance Foundation Trials, LLC. (1) · City of Hope Medical Center (1) · DualityBio Inc. (1) · ECOG-ACRIN Cancer Research Group (1) · Enliven Therapeutics (1) · First Affiliated Hospital Xi'an Jiaotong University (1)
United States (44) · China (12) · France (10) · Spain (10) · Germany (9) · Belgium (8) · Canada (8) · Italy (8) · South Korea (8) · United Kingdom (7) · Australia (5) · Brazil (5) · Netherlands (5) · Russia (5) · Taiwan (5)
Jenny C Chang, MD (2) · Nancy Lin, MD (2) · Sara Tolaney, MD MPH (2) · Sara Tolaney, MD, MPH (2) · Adrienne Waks, MD (1) · Alan L Ho (1) · Charles Swanton (1) · Ciara C O'Sullivan (1) · Corinna Palanca-Wessels, MD, PhD (1) · Ecaterina Dumbrava, MD (1) · Einsley Janowski, MD, PhD (1) · Elaine K. Wong, M.Sc., M.D. (1) · Ellie Guardino, M.D., PhD. (1) · Ellie Guardino, MD/PhD (1)
PMID 22437872, PMID 23020162, PMID 23382472, PMID 24733796, PMID 24793816, PMID 24887458, PMID 25713436, PMID 26586415, PMID 26598545, PMID 26834058, PMID 27052654, PMID 28526536, PMID 28526538, PMID 28733983, PMID 29955792, PMID 30860945, PMID 31235441, PMID 31442103, PMID 31477168, PMID 31558424, PMID 32270710, PMID 32463741, PMID 33048619, PMID 34077270, PMID 35133871, PMID 35138919, PMID 35173164, PMID 35320644, PMID 35964548, PMID 36252998, PMID 36351402, PMID 36450763, PMID 36495879, PMID 36705597, PMID 37053535, PMID 37179020, PMID 37207306, PMID 37322121, PMID 37561451, PMID 37934000, PMID 38059424, PMID 38300710, PMID 38442809, PMID 38591867, PMID 38650031, PMID 38825627, PMID 38935923, PMID 38979893, PMID 39368039, PMID 39666929
U10CA180820 (3), P30CA015083 (2), U24CA196172 (2), 2009 (1), 2018 (1), 2023 (1), P30CA015704 (1), P30CA060553 (1), U10CA180868 (1), U10CA180888 (1)